named programs · 1 · from sources
What they call their work
Sohn Investment Conference
Annual event convening investors and financial leaders to share investment insights, with proceeds supporting pediatric medical research and treatment initiatives
activities · 4 groups
What they do
-
Cancer Research Funding 2 activities
- Funding advanced research infrastructure and therapiesFinances high-impact scientific tools and medical research, including the acquisition of a high-performance supercomputer at The Rockefeller University and funding research into novel monoclonal antibody therapy for COVID-19 during 2020 and 2021.
- Funding pediatric cancer and childhood disease researchSupports efforts toward the treatment and cure of pediatric cancer and other childhood diseases through targeted grants, including funding for early-career scientists via the Damon Runyon-Sohn Pediatric Cancer Fellowship Award, with commitments ranging from nearly $500,000 to $1 million.
-
-
Art Museum Funding and Support 1 activity
- Funding arts programming for hospitalized childrenSupports Artworks, a program that delivers creative and performing arts services to children and young adults across 35 hospitals in the New York Metropolitan area.
-
-
Hospital and Medical Center Support 1 activity
- Funding pediatric oncology facility improvements and survivorship programsProvides seed funding for major renovations such as the Pediatric Infusion Center at New York Presbyterian and launched the Sohn-Manning Pediatric Cancer Survivorship Program at Hackensack University Medical Center in 2016 to improve care environments and long-term outcomes for pediatric cancer patients.
-
-
Charity Event Organization 1 activity
- Raising funds through investment conferencesHosts annual Sohn Investment Conferences that bring together leading investors to present investment ideas, generating charitable donations and fees from presenters, sponsors, advisors, and participants in support of the Foundation’s mission.
-
financials · form 990 · fy2024
revenue
Total revenue$-136K
Contributions & grants$1.17M—
Program service revenue$0—
Investment income$-327—
Other revenue$-1.30M
expenses
Total expenses$162K
Program expenses14%
Admin / overhead86%
Fundraising0%
Salaries & benefits$0
Grants paid out$22K
Largest expense lineProfessional Fees
balance sheet
Total assets$349K
Cash$183K
Investments$0
Liabilities$65K
Net assets$284K
Liquid reserves13.5 mo
4 years on record · 2020–2024 · YoY revenue -117.7%
leadership · form 990 part vii · fy2024
Who runs it
board members · 3
- DANIEL NIR — DIRECTOR AND PRESIDENT
- EVAN SOHN — DIRECTOR AND VP/TREASURER
- GRAHAM DUNCAN — DIRECTOR, CHAIR AND CEO
relationships · 28
Who they work with
- Columbia University Medical Center Partner — Funded the Sohn Precision Medicine Program to provide genomic testing for high-risk pediatric cancer patients.
- Columbia University Medical Center Partner — Partner institution hosting The Sohn Precision Medicine Program for high-risk pediatric cancer patients.
- Damon Runyon Cancer Research Foundation Partner — Co-funds the Damon Runyon-Sohn Pediatric Cancer Fellowship Award for researchers in pediatric oncology.
- Damon Runyon Cancer Research Foundation Partner — Collaborates to fund the Damon Runyon-Sohn Pediatric Cancer Fellowship Award for early-career researchers.
- Damon Runyon Cancer Research Foundation Partner — Partner organization co-sponsoring the Damon Runyon-Sohn Pediatric Cancer Fellowship Award.
- Grants in New York City Partner — Collaborates with researchers and institutions in New York City to inspire scientific collaboration.
- Hackensack University Medical Center Partner — Funded the Sohn-Manning Pediatric Cancer Survivorship Program and clinical trials through the Children’s Cancer Institute.
- Hackensack University Medical Center Partner — Partner institution where the Sohn-Manning Pediatric Cancer Survivorship Program was launched in 2016.
- Memorial Sloan Kettering Cancer Center Partner — Partner institution supported through funding for pediatric cancer research and patient care initiatives.
- Memorial Sloan Kettering Cancer Center Partner — Supported through funding for MSK Kids, a pediatric cancer program advancing research and care.
- Mount Sinai Kravis Children's Hospital Partner — Funded The Lion’s Den, a technology-enabled center for pediatric cancer patients.
- Mount Sinai Kravis Children's Hospital Partner — Partner institution where The Sohn Conference Foundation supports The Lion’s Den, a technology-enabled center for pediatric cancer patients.
- NYU Langone Partner — Funded a brain diagnostic tumor program and construction of a new children’s hospital with specialized cancer care rooms.
- NYU Langone Partner — Partner institution receiving funding for a brain tumor diagnostic program and children’s hospital development.
- New York Genome Center Partner — Funds the Sohn Collaborative Research Project for Pediatric Cancer, a multi-institutional genomics initiative.
- New York Genome Center Partner — Partner institution leading the Sohn Collaborative Research Project for Pediatric Cancer with multiple academic partners.
- New York Presbyterian Partner — Partner institution that received seed funding for the renovation of its Pediatric Infusion Center.
- New York Presbyterian Partner — Provided seed funding for the renovation of the Pediatric Infusion Center to serve children in a specialized environment.
- Pershing Square Cancer Research Partner — Funds high-risk, high-reward research by top New York-based scientists in cancer.
- Pershing Square Cancer Research Partner — Partner initiative providing flexible funding for high-risk, high-reward cancer research by top scientists in New York.
- Pershing Square Sohn Cancer Research Alliance Partner — Partners to support early-career cancer researchers through prize funding and research advancement.
- Sohn Investment Conferences Network — Annual investment conferences organized by the Foundation as part of its core programming.
- The Rockefeller University Partner — Funded for acquisition of a supercomputer and development of monoclonal antibody therapies.
- The Rockefeller University Partner — Partner institution that received funding for a supercomputer and monoclonal antibody therapy research.
- Tri-Institutional Therapeutics Discovery Institute Partner — Funds collaborative drug discovery research in leukemia and melanoma across Memorial Sloan Kettering, Rockefeller University, and Weill Cornell.
- Tri-Institutional Therapeutics Discovery Institute Partner — Partner consortium funded for collaborative research into leukemia and melanoma involving Memorial Sloan Kettering, Rockefeller University, and Weill Cornell.
- Weill Cornell Medicine Partner — Funded to acquire state-of-the-art equipment for studying cancer metastasis and therapy targets.
- Weill Cornell Medicine Partner — Partner institution receiving funding for state-of-the-art research equipment to study cancer metastasis and therapeutic targets.
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Collaborative Research Consortium Modelmethodology: collaborative_research_consortiumBy funding multi-institutional teams of leading researchers, the organization accelerates progress in pediatric cancer genomics, because cross-institutional collaboration enables data sharing, reduces duplication, and leverages diverse expertise to achieve discoveries faster than isolated labs could.
- Investor-Approach to Grantmakingmethodology: investor-approach-to-grantmakingBy applying a selective, investor-like framework to philanthropy, the organization identifies and funds high-impact opportunities in pediatric cancer research and public health innovation, because disciplined capital allocation analogous to venture investing increases the likelihood of breakthrough outcomes.
- Strategic Philanthropy Through Financial Community Engagementmethodology: philanthropy-through-financeBy organizing investment conferences and leveraging networks in the finance sector, the organization generates philanthropic funding and awareness for pediatric cancer research, because engaging high-capacity donors through familiar platforms increases capital flow to high-priority research initiatives.